with 4.9/5.0 stars from 9,000+ reviews on the apple app store as of march 2020 , the dario tm blood sugar monitor 's user-centric approach is loved by tens of thousands of customers around the globe . we are rapidly expanding solutions for additional chronic conditions such as hypertension , using a performance-based approach to improve the health of users managing chronic disease . 51 our flagship product , dario , which we also refer to as our dario smart diabetes management solution , is a mobile , real-time , cloud-based , diabetes management solution based on an innovative , multi-feature software application to track and monitor all facets of diabetes , combined with a stylish , ‘ all-in-one ' , pocket-sized , blood glucose monitoring device , which we call the dario blood glucose monitoring system , that essentially turns a smartphone into a glucometer . in addition , our product offerings will focus on the newly launched darioengage software platform , where we digitally engage with dario users , assist them in monitoring their chronic illnesses and provide them with coaching , support , digital communications and real time alerts , trends and pattern analysis . the darioengage platform can be leveraged by our potential partners , such as clinics , health care service providers , employers and payers for scalable monitoring of people with diabetes in a cost-effective manner , which we expect will open for us additional revenue streams . finally , we intend to utilize the data we obtain from our dario smart diabetes management solution and darioengage platform to develop our upcoming healthcare analytics program , dario intelligence . as such , we intend to develop our solutions such that they will span the full spectrum of disease monitoring , user-centric engagement , coaching tools , and big data and intelligence solutions . we have obtained regulatory clearance or approval for the dario blood glucose monitoring system in the u.s. , canada , the e.u . , israel and australia , among others . we believe that our targeted health platform is a highly personalized preventative and proactive approach to health improvement based on individual behavior and treatment , tailored to each person 's unique profile . our principal operating subsidiary , labstyle innovation ltd. , is an israeli company with its headquarters in caesarea , israel . we were formed on august 11 , 2011 as a delaware corporation . we commenced a commercial launch of our free application in the united kingdom in late 2013 and commenced an initial soft launch of the full dario solution ( including the app and the dario blood glucose monitoring system ) in selected jurisdictions in march 2014. we continued to scale up launch during 2014 in the united kingdom , the netherlands and new zealand , and during 2015 in australia , israel and canada , with the goal of collecting customer feedback to refine our longer-term roll-out strategy . we are consistently adding new additional features and functionality in making dario the new standard of care in diabetes data management . through our israeli subsidiary , labstyle innovation ltd. , our plan of operations is to continue the development of our software and hardware offerings and related technology . during 2015 , we successfully launched the dario smart diabetes management solution according to plan and are currently expanding the launch to other jurisdictions . in 2016 , we established our direct to consumer model in the u.s. to achieve higher and faster penetration into the market during the launch phase . we have invested in a robust digital marketing department with in-house platforms , experienced personnel and robust infrastructures to support expected growth of users and online subscribers in this market . during the third quarter of 2016 we expanded these efforts to include australia as well . in 2017 , we expanded our direct to consumer marketing efforts in the united kingdom in cooperation with our local distributor and launched similar marketing efforts in germany . in support of these goals , we intend to utilize our funds for the following activities : · ramp up of mass production , marketing and distribution and sales efforts related to the dario smart diabetes management solution and the darioengage platform ; · develop our customer support and telemarketing services in order to support the expect growth of our revenues and the increase of user , and service provider who will use our platform to better serve people with diabetes and improve their clinical outcome ; · continued product and software development , and related activities ( including costs associated with application development and data storage capabilities as well as any necessary design modifications to the various elements of the dario smart diabetes management solution , the darioengage platform and the dario intelligence tools and capabilities ) ; · continued work on registration of our patents worldwide ; · regulatory and quality assurance matters ; · professional fees associated with being a publicly reporting company ; and · general and administrative matters . 52 in september 2019 we formed a strategic alliance with dance biopharm holdings , inc. , a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies to expand access to a personalized digital health management platform for patients with chronic diseases . also in september 2019 , we received a notice of allowance from the u.s. patent and trademark office titled “ systems and methods for enabling optical transmission of data between a sensor and a smart device . story_separator_special_tag additionally , readers are advised that available resources may be consumed more rapidly than currently anticipated , resulting in the need for additional funding sooner than expected . should this occur , we will need to seek additional capital earlier than anticipated in order to fund ( 1 ) further development and , if needed ( 2 ) our efforts to obtain regulatory clearances or approvals necessary to be able to commercially launch dario , darioengage and dario intelligence , ( 3 ) expenses which will be required in order to expand manufacturing of our products , ( 4 ) sales and marketing efforts and ( 5 ) general working capital . such funding may be unavailable to us on acceptable terms , or at all . our failure to obtain such funding when needed could create a negative impact on our stock price or could potentially lead to the failure of our company . this would particularly be the case if we are unable to commercially distribute our products and services in the jurisdictions and in the timeframes we expect . 58 cash flows the following tables sets forth selected cash flow information for the periods indicated : replace_table_token_2_th net cash used in operating activities net cash used in operating activities was $ 15,725,000 for the year ended december 31 , 2019 compared to $ 11,470,000 used in operations for the same period in 2018. cash used in operations increased mainly due to an increase in our operating expenses , and offset by a decrease in our trade payables and other accounts payable and accrued expenses . net cash used in investing activities net cash used for investing activities was $ 113,000 for the year ended december 31 , 2019 compared to cash used in investing activities of $ 72,000 for the year ended december 31 , 2018. cash used in investing activities increased mainly due to higher investment in fixed assets . net cash provided by financing activities net cash provided by financing activities was $ 25,247,000 for the year ended december 31 , 2019 compared to $ 18,743,000 for the year ended december 31 , 2018. during the year ended december 31 , 2019 , we raised net proceeds in an amount of approximately $ 25,247,000 through our may and december 2019 offerings . contractual obligations set forth below is a summary of our current obligations as of december 31 , 2019 to make future payments due by the period indicated below , excluding payables and accruals . we expect to be able to meet our obligations in the ordinary course . operating lease obligations are for motor vehicle and real property leases which we use in our business . purchasing obligations consists of outstanding purchase orders for materials and services from our vendors . replace_table_token_3_th off-balance sheet arrangements we did not have during the periods presented , and we do not currently have , any off-balance sheet arrangements as defined under securities and exchange commission rules . contingencies we account for our contingent liabilities in accordance with asc 450 “ contingencies “ . a provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated . 59 with respect to legal matters , provisions are reviewed and adjusted to reflect the impact of negotiations , estimated settlements , legal rulings , advice of legal counsel and other information and events pertaining to a particular matter . currently , we are not a party to any ligation that we believe could have a material adverse effect on our business , financial position , results of operations or cash flows . recently issued and adopted accounting pronouncements in may 2014 , the financial accounting standards board ( the “ fasb ” ) issued asc 606. the standard replaced the revenue recognition guidance in u.s. generally accepted accounting principles under asc 605 , and was required to be applied retrospectively to each prior period presented or applied using a modified retrospective method with the cumulative effect recognized in the beginning retained earnings during the period of initial application . subsequently , the fasb issued several additional accounting standard updates ( each an “ asu ” ) related to asu no . 2014-09 , collectively referred to as the “ new revenue standards , ” which became effective for us beginning january 1 , 2019. we adopted the standard using the modified retrospective method . the adoption of asc 606 did not have a significant impact on our consolidated financial statements . in february 2016 , the fasb issued asu no . 2016-02 , “ leases ” ( topic 842 ) ( “ asc 842 ” ) . the standard requires lessees to recognize almost all leases on the balance sheet as a right-of-use ( “ rou ” ) asset and a lease liability and requires leases to be classified as either an operating or a finance type lease . the standard excludes leases of intangible assets or inventory . the standard became effective for us beginning january 1 , 2019. we adopted asc 842 using the modified retrospective approach , by applying the new standard to all leases existing at the date of initial application . results and disclosure requirements for reporting periods beginning after january 1 , 2019 are presented under asc 842 , while prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under asc 840. we elected the package of practical expedients permitted under asc 842 , which also allowed us to carry forward historical lease classifications . we also elected the practical expedient related to treating lease and non-lease components as a single lease component for all equipment leases as well as electing a policy exclusion permitting leases with an original lease term of less than one year to be excluded from the rou assets and lease liabilities . in november 2016 ,

liquidity and capital resources as of december 31 , 2019 , we had approximately $ 20,395,000 in cash and cash equivalents compared to $ 10,997,000 at december 31 , 2018. we have experienced cumulative losses of $ 110,145,000 from inception ( august 11 , 2011 ) through december 31 , 2019 , and have a stockholders ' equity of $ 18,894,000 at december 31 , 2019. in addition , we have not completed our efforts to establish a stable recurring source of revenues sufficient to cover our operating costs and expect to continue to generate losses for the foreseeable future . there are no assurances that we will be able to obtain an adequate level of financing needed for our near term requirements or the long-term development and commercialization of our product . these conditions raise substantial doubt about our ability to continue as a “ going concern. ” since inception , we have financed our operations primarily through private placements and public offerings of our common stock and warrants to purchase shares of our common stock , receiving aggregate net proceeds totaling $ 96,426,000 as of december 31 , 2019. on march 3 , 2016 , we conducted a public offering , pursuant to which we issued 66,667 shares of common stock and warrants exercisable for an aggregate of 66,667 shares of common stock for an aggregate net consideration of $ 5,038,000. concurrently with our public offering , on march 3 , 2016 , we conducted a concurrent private placement pursuant to which we issued 27,778 units , with each unit consisting of one share of common stock and one warrant to purchase 1.2 shares of common stock , such that an aggregate of 27,778 shares of common stock and a warrant to exercisable for an aggregate of 33,334 shares of common stock was issued and sold for an aggregate net consideration of approximately $ 2,500,000. on january 9 , 2017 , we commenced a private placement offering of up to $ 5,100,000 consisting of up to 91,072 shares of common stock and warrants to purchase up to 91,072 shares of common stock .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources as of december 31 , 2019 , we had approximately $ 20,395,000 in cash and cash equivalents compared to $ 10,997,000 at december 31 , 2018. we have experienced cumulative losses of $ 110,145,000 from inception ( august 11 , 2011 ) through december 31 , 2019 , and have a stockholders ' equity of $ 18,894,000 at december 31 , 2019. in addition , we have not completed our efforts to establish a stable recurring source of revenues sufficient to cover our operating costs and expect to continue to generate losses for the foreseeable future . there are no assurances that we will be able to obtain an adequate level of financing needed for our near term requirements or the long-term development and commercialization of our product . these conditions raise substantial doubt about our ability to continue as a “ going concern. ” since inception , we have financed our operations primarily through private placements and public offerings of our common stock and warrants to purchase shares of our common stock , receiving aggregate net proceeds totaling $ 96,426,000 as of december 31 , 2019. on march 3 , 2016 , we conducted a public offering , pursuant to which we issued 66,667 shares of common stock and warrants exercisable for an aggregate of 66,667 shares of common stock for an aggregate net consideration of $ 5,038,000. concurrently with our public offering , on march 3 , 2016 , we conducted a concurrent private placement pursuant to which we issued 27,778 units , with each unit consisting of one share of common stock and one warrant to purchase 1.2 shares of common stock , such that an aggregate of 27,778 shares of common stock and a warrant to exercisable for an aggregate of 33,334 shares of common stock was issued and sold for an aggregate net consideration of approximately $ 2,500,000. on january 9 , 2017 , we commenced a private placement offering of up to $ 5,100,000 consisting of up to 91,072 shares of common stock and warrants to purchase up to 91,072 shares of common stock .
```    
 Suspicious Activity Report : with 4.9/5.0 stars from 9,000+ reviews on the apple app store as of march 2020 , the dario tm blood sugar monitor 's user-centric approach is loved by tens of thousands of customers around the globe . we are rapidly expanding solutions for additional chronic conditions such as hypertension , using a performance-based approach to improve the health of users managing chronic disease . 51 our flagship product , dario , which we also refer to as our dario smart diabetes management solution , is a mobile , real-time , cloud-based , diabetes management solution based on an innovative , multi-feature software application to track and monitor all facets of diabetes , combined with a stylish , ‘ all-in-one ' , pocket-sized , blood glucose monitoring device , which we call the dario blood glucose monitoring system , that essentially turns a smartphone into a glucometer . in addition , our product offerings will focus on the newly launched darioengage software platform , where we digitally engage with dario users , assist them in monitoring their chronic illnesses and provide them with coaching , support , digital communications and real time alerts , trends and pattern analysis . the darioengage platform can be leveraged by our potential partners , such as clinics , health care service providers , employers and payers for scalable monitoring of people with diabetes in a cost-effective manner , which we expect will open for us additional revenue streams . finally , we intend to utilize the data we obtain from our dario smart diabetes management solution and darioengage platform to develop our upcoming healthcare analytics program , dario intelligence . as such , we intend to develop our solutions such that they will span the full spectrum of disease monitoring , user-centric engagement , coaching tools , and big data and intelligence solutions . we have obtained regulatory clearance or approval for the dario blood glucose monitoring system in the u.s. , canada , the e.u . , israel and australia , among others . we believe that our targeted health platform is a highly personalized preventative and proactive approach to health improvement based on individual behavior and treatment , tailored to each person 's unique profile . our principal operating subsidiary , labstyle innovation ltd. , is an israeli company with its headquarters in caesarea , israel . we were formed on august 11 , 2011 as a delaware corporation . we commenced a commercial launch of our free application in the united kingdom in late 2013 and commenced an initial soft launch of the full dario solution ( including the app and the dario blood glucose monitoring system ) in selected jurisdictions in march 2014. we continued to scale up launch during 2014 in the united kingdom , the netherlands and new zealand , and during 2015 in australia , israel and canada , with the goal of collecting customer feedback to refine our longer-term roll-out strategy . we are consistently adding new additional features and functionality in making dario the new standard of care in diabetes data management . through our israeli subsidiary , labstyle innovation ltd. , our plan of operations is to continue the development of our software and hardware offerings and related technology . during 2015 , we successfully launched the dario smart diabetes management solution according to plan and are currently expanding the launch to other jurisdictions . in 2016 , we established our direct to consumer model in the u.s. to achieve higher and faster penetration into the market during the launch phase . we have invested in a robust digital marketing department with in-house platforms , experienced personnel and robust infrastructures to support expected growth of users and online subscribers in this market . during the third quarter of 2016 we expanded these efforts to include australia as well . in 2017 , we expanded our direct to consumer marketing efforts in the united kingdom in cooperation with our local distributor and launched similar marketing efforts in germany . in support of these goals , we intend to utilize our funds for the following activities : · ramp up of mass production , marketing and distribution and sales efforts related to the dario smart diabetes management solution and the darioengage platform ; · develop our customer support and telemarketing services in order to support the expect growth of our revenues and the increase of user , and service provider who will use our platform to better serve people with diabetes and improve their clinical outcome ; · continued product and software development , and related activities ( including costs associated with application development and data storage capabilities as well as any necessary design modifications to the various elements of the dario smart diabetes management solution , the darioengage platform and the dario intelligence tools and capabilities ) ; · continued work on registration of our patents worldwide ; · regulatory and quality assurance matters ; · professional fees associated with being a publicly reporting company ; and · general and administrative matters . 52 in september 2019 we formed a strategic alliance with dance biopharm holdings , inc. , a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies to expand access to a personalized digital health management platform for patients with chronic diseases . also in september 2019 , we received a notice of allowance from the u.s. patent and trademark office titled “ systems and methods for enabling optical transmission of data between a sensor and a smart device . story_separator_special_tag additionally , readers are advised that available resources may be consumed more rapidly than currently anticipated , resulting in the need for additional funding sooner than expected . should this occur , we will need to seek additional capital earlier than anticipated in order to fund ( 1 ) further development and , if needed ( 2 ) our efforts to obtain regulatory clearances or approvals necessary to be able to commercially launch dario , darioengage and dario intelligence , ( 3 ) expenses which will be required in order to expand manufacturing of our products , ( 4 ) sales and marketing efforts and ( 5 ) general working capital . such funding may be unavailable to us on acceptable terms , or at all . our failure to obtain such funding when needed could create a negative impact on our stock price or could potentially lead to the failure of our company . this would particularly be the case if we are unable to commercially distribute our products and services in the jurisdictions and in the timeframes we expect . 58 cash flows the following tables sets forth selected cash flow information for the periods indicated : replace_table_token_2_th net cash used in operating activities net cash used in operating activities was $ 15,725,000 for the year ended december 31 , 2019 compared to $ 11,470,000 used in operations for the same period in 2018. cash used in operations increased mainly due to an increase in our operating expenses , and offset by a decrease in our trade payables and other accounts payable and accrued expenses . net cash used in investing activities net cash used for investing activities was $ 113,000 for the year ended december 31 , 2019 compared to cash used in investing activities of $ 72,000 for the year ended december 31 , 2018. cash used in investing activities increased mainly due to higher investment in fixed assets . net cash provided by financing activities net cash provided by financing activities was $ 25,247,000 for the year ended december 31 , 2019 compared to $ 18,743,000 for the year ended december 31 , 2018. during the year ended december 31 , 2019 , we raised net proceeds in an amount of approximately $ 25,247,000 through our may and december 2019 offerings . contractual obligations set forth below is a summary of our current obligations as of december 31 , 2019 to make future payments due by the period indicated below , excluding payables and accruals . we expect to be able to meet our obligations in the ordinary course . operating lease obligations are for motor vehicle and real property leases which we use in our business . purchasing obligations consists of outstanding purchase orders for materials and services from our vendors . replace_table_token_3_th off-balance sheet arrangements we did not have during the periods presented , and we do not currently have , any off-balance sheet arrangements as defined under securities and exchange commission rules . contingencies we account for our contingent liabilities in accordance with asc 450 “ contingencies “ . a provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated . 59 with respect to legal matters , provisions are reviewed and adjusted to reflect the impact of negotiations , estimated settlements , legal rulings , advice of legal counsel and other information and events pertaining to a particular matter . currently , we are not a party to any ligation that we believe could have a material adverse effect on our business , financial position , results of operations or cash flows . recently issued and adopted accounting pronouncements in may 2014 , the financial accounting standards board ( the “ fasb ” ) issued asc 606. the standard replaced the revenue recognition guidance in u.s. generally accepted accounting principles under asc 605 , and was required to be applied retrospectively to each prior period presented or applied using a modified retrospective method with the cumulative effect recognized in the beginning retained earnings during the period of initial application . subsequently , the fasb issued several additional accounting standard updates ( each an “ asu ” ) related to asu no . 2014-09 , collectively referred to as the “ new revenue standards , ” which became effective for us beginning january 1 , 2019. we adopted the standard using the modified retrospective method . the adoption of asc 606 did not have a significant impact on our consolidated financial statements . in february 2016 , the fasb issued asu no . 2016-02 , “ leases ” ( topic 842 ) ( “ asc 842 ” ) . the standard requires lessees to recognize almost all leases on the balance sheet as a right-of-use ( “ rou ” ) asset and a lease liability and requires leases to be classified as either an operating or a finance type lease . the standard excludes leases of intangible assets or inventory . the standard became effective for us beginning january 1 , 2019. we adopted asc 842 using the modified retrospective approach , by applying the new standard to all leases existing at the date of initial application . results and disclosure requirements for reporting periods beginning after january 1 , 2019 are presented under asc 842 , while prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under asc 840. we elected the package of practical expedients permitted under asc 842 , which also allowed us to carry forward historical lease classifications . we also elected the practical expedient related to treating lease and non-lease components as a single lease component for all equipment leases as well as electing a policy exclusion permitting leases with an original lease term of less than one year to be excluded from the rou assets and lease liabilities . in november 2016 ,

